Next-generation solutions for your diagnostic needs

Built by a robotics company from the ground up, we combine our leading automated lab platform with world-renowned scientists to increase your testing capacity.

Meeting your testing needs through innovation

PRL was established in 2020 in response to the COVID-19 pandemic to address the pressing need to make rapid, accurate and low-cost testing equitably accessible to all populations.

We leverage advancements in PCR technology to help you improve patient management by reducing diagnostic test result turnaround time and the risk of outbreaks—all at a fraction of market cost.

From infectious disease testing and routine health screening to non-diagnostic sequencing services, download our test menu to view current and upcoming offerings, including:

  • SARS-CoV-2 testing and non-diagnostic whole-genome sequencing
  • Concise Respiratory Panel with 4 common targets: SARS-CoV-2, Influenza A, Influenza B, RSV
  • Comprehensive Respiratory Panel with 21 targets COMING SOON!*
  • Sexually Transmitted Infection Panel with 3 targets: Chlamydia, Gonorrhea & Trichomoniasis

Tests run in each PRL laboratory are independently developed and validated at their respective facility; performance of tests may vary.

The PRL SCV2 Test and the Concise Respiratory Panel contain a test for COVID-19, which has not been FDA cleared or approved. For our testing in our Maryland and NY labs, the COVID-19 test has been authorized by clinical laboratory authorities in the State of New York and the State of Maryland for use by the authorized laboratory in each such state. For our California lab, an EUA for the COVID-19 test was submitted to the FDA on August 12, 2021 and is under review.

For testing in PRL’s Maryland and California labs, the STI Panel is regulated by clinical laboratory authorities in the States of Maryland and California for use by the authorized laboratory in each such state. For PRL’s New York lab, the STI Panel is forthcoming. The STI Panel is not currently available for samples received from the states of New York, Pennsylvania and Rhode Island.

* Timelines are tentative and subject to change. Upcoming tests are in development and subject to future modifications and regulatory review. Unless explicitly stated, PRL makes no representations regarding state or federal regulatory approval, turnaround times, or performance for any test listed herein.